According to the results of an international study involving researchers from the Clinical Oncology group at the Sant Pau Research Institute, led by Dr. Teresa Ramon y Cajal, the follow-up with magnetic resonance imaging in women with mutations in the BRCA1 genes who have a high risk of developing breast cancer throughout their lives significantly reduces mortality without the need for preventive mastectomy.
L’Institut de Recerca Sant Pau (IR Sant Pau) i el Banc de Sang i Teixits (BST) han signat un acord de col·laboració destinat a impulsar el desenvolupament i la producció de medicaments innovadors.
L’acord, que representa una aliança pionera entre dues institucions capdavanteres en el camp de la salut, estableix les bases per a la creació d’un node conjunt que comptarà amb instal·lacions preparades per a la producció de teràpies avançades, incloent-hi les cèl·lules CAR-T.
A group of scientists from various hospitals and research centers in Catalonia, led by Drs. Álvaro Carbayo and Ricard Rojas, researchers from the Neuromuscular Diseases Group at the Sant Pau Research Institute, in collaboration with Dr. Sergi Borrego-Écija and Dr. Ellen Gelpi from the Alzheimer’s Disease and other Cognitive Disorders Group and the Neurological Tissue Bank of IDIBAPS, have published a study in the journal Brain that reveals connections between two devastating brain diseases: Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia.
The detection of phosphorylated TAU 217 protein (p-tau217) in plasma has shown high precision in identifying pathological accumulations of beta-amyloid and TAU proteins. This precision is comparable to traditional biomarker detection in cerebrospinal fluid, as revealed by a recent study published in JAMA Neurology. Researchers from the Research Area in Neurological Diseases, Neuroscience, and Mental Health at the Sant Pau Research Institute, led by Dr. Juan Fortea, Director Sof the Memory Unit at the Neurology Department of the same hospital, participated in the study. These results pave the way for diagnosing Alzheimer’s disease through a blood test.
Today, we celebrated the Sant Pau Research Day with genomics and rare diseases taking center stage. The day began with an introduction by Dr. Xavier Prats Monné, president of the board of the Sant Pau Research Institute (IR Sant Pau), who highlighted the talent and excellent work carried out by professionals in this field at Sant Pau.
La Marató de TV3 Foundation will fund 8 cardiovascular health projects coordinated from the Sant Pau Research Institute, thanks to the funds raised in the last edition, which was specifically dedicated to these diseases. In total, Sant Pau will receive €2,296,961.25, which will be allocated to leading projects on diseases such as myocardial infarction, stroke, atherosclerosis, hypercholesterolemia, or arrhythmias, some of them in collaboration with other research centers. Additionally, researchers from Sant Pau are also involved in two selected projects coordinated from other centers.
A study conducted at the Research Institute of the Hospital de la Santa Creu i Sant Pau – IIB Sant Pau suggests that certain microRNAs (miRNAs) may be useful as non-invasive biomarkers for the early diagnosis of lymph node metastasis in patients with early-stage breast cancer. The research, led by Dr. Agustí Barnadas, head of the Clinical Oncology research group at IIB Sant Pau and head of the Medical Oncology service at the same hospital, focused on patients with early-stage breast cancer with estrogen receptor-positive (ER-positive) tumors.
A study conducted by researchers at the Research Institute from Hospital Santa Creu i Sant Pau – IIB Sant Pau in Barcelona, Spain, has shown that deep brain stimulation of the subcallosal cingulate gyrus (SCG-DBS) can offer significant and lasting benefits for treating depression. The results of this research support the idea that this surgical intervention could be an effective alternative for patients suffering from severe major depression who have not responded to conventional treatments.
Sant Pau creates a new transversal research program on Women’s Health and Gender. The Research Institute of Hospital de la Santa Creu i Sant Pau – IIB Sant Pau has launched a new cross-cutting research program to promote a gender perspective in all of its research areas and groups.
The Research Institute of the Hospital de la Santa Creu i Sant Pau – IIB Sant Pau has developed a new CAR-T 19 immunotherapy drug that has just begun to be administered, as part of a clinical trial, to patients with certain types of lymphoma (diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma) who have not responded to other treatments. With this new and unique therapeutic proposal in Spain for these patients, Sant Pau offers its second academic advanced therapy medicinal product, which means that it has been entirely produced and developed at Sant Pau. This new CAR-T 19 is characterized by being enriched in memory T lymphocytes, which are longer-lasting over time, with the aim of having greater efficacy against the disease.
Cancer patients are at high risk of suffering a thrombotic event that can worsen their prognosis and quality of life. Researchers from the Research Group on Genomics of Complex Diseases of the Research Institute of the Hospital de la Santa Creu i Sant Pau – IIB Sant Pau, led by Dr. José Manuel Soria, and the Medical Oncology Service of the Gregorio Marañón General University Hospital in Madrid, led by Dr. Andrés Muñoz, within the framework of the Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM) have developed and validated a new tool or score, called ONCOTHROMB, which for the first time combines clinical data and genomics of the patient. This tool has shown an excellent predictive capacity of the risk of suffering venous thromboembolic events by cancer patients undergoing chemotherapy outpatient treatment.
The results, published by the prestigious journal Nature, show that the deficiency in the cells’ natural process to repair the damage produced by chemicals that damage DNA, called aldehydes, is responsible for the risk of developing carcinoma of head and neck squamous cells.
An international study in which researchers from the Dementia Neurobiology Group and the Memory Unit of the Research Institute of the Hospital de la Santa Creu i Sant Pau – IIB Sant Pau participated, leaded by Alberto Lleó, discovered two new genes associated with a significantly increased risk of developing Alzheimer’s disease.
El comitè científic del Congrés de Cirurgians Neurològics (CNS) ha triat un estudi de l’Institut de Recerca de l’Hospital de Santa Creu i Sant Pau – IIB Sant Pau com a millor manuscrit de l’any 2022 a l’àrea de Cirurgia neurofuncional i estereotàxica. Es tracta d’un estudi publicat a la revista Neurosurgery, els autors principals del qual són Juan Ángel Aibar-Durán, del Servei de Neurocirurgia, i Francisco Javier de Diego, del servei de Psiquiatria d’aquest hospital.
An international study, in which the Research Institute of the Hospital de la Santa Creu i Sant Pau – IIB Sant Pau has participated, has found 89 genes involved in the risk of developing a stroke, of which 61 had not been previously described. This is the largest and most comprehensive study conducted ever.
The World Health Organization (WHO) proclaimed September 21 World Alzheimer’s Day in 1994 under the auspices of Alzheimer’s Disease International (ADI)..
Science will be the protagonist this year in the free entry day that the Recinto Modernista de Sant Pau has scheduled for the next September, 24th to celebrate the Fiestas de la Mercè and on the occasion of the 30th anniversary of the Research Institute of the Hospital de la Santa Creu i Sant Pau.
The Board of Trustees of the Santa Creu i Sant Pau Hospital Research Institute Foundation (IR-Sant Pau) has approved the designation of Mr. Jaume Bacardit as new manager of the institute. He has more than 25 years of experience in the international biomedical research sector and is an expert in finance and economic management. His expertise will be key to facing the institute’s challenges.
